G-Link CAR-T Delivery Platform Showcased at ASGCT

Why It Matters

By simplifying vector engineering and manufacturing, G‑Link could accelerate the rollout of next‑generation CAR‑T therapies, lowering costs and expanding access to cell‑based treatments across oncology.

Key Takeaways

• G‑Link repurposes existing lentiviral vectors for in‑vivo CAR‑T delivery.
• Platform reduces development time by eliminating extensive vector redesign.
• Improves ex‑vivo T‑cell transduction efficiency without new vector engineering.
• Enables off‑the‑shelf immunotherapies, shortening manufacturing cycles.
• Vyriad plans clinical start for VV169 later this year.

Pulse Analysis

The cell‑therapy landscape has been dominated by ex‑vivo engineered CAR‑T products, which require weeks of patient‑specific manufacturing and complex logistics. While these approaches have delivered impressive remission rates in hematologic cancers, their high cost and limited scalability hinder broader adoption, especially for solid tumors. Industry analysts therefore view in‑vivo delivery of CAR constructs as the next frontier, promising off‑the‑shelf solutions that can be administered like conventional drugs. However, achieving efficient, targeted gene transfer inside the body remains a technical bottleneck that has slowed progress.

Vyriad’s G‑Link platform tackles that bottleneck with a modular protein adapter that caps existing lentiviral vectors and redirects them to chosen cell‑surface receptors. By preserving the wild‑type backbone, the system avoids the time‑intensive re‑engineering traditionally required for each new target, cutting development cycles from months to weeks. Early data suggest the adapter also boosts transduction rates in ex‑vivo T‑cell cultures, potentially simplifying manufacturing even for conventional CAR‑T pipelines. The technology’s plug‑and‑play nature positions it as a versatile tool for both in‑vivo therapies and rapid prototyping of novel cell‑based drugs.

The announcement arrives as investors pour capital into next‑generation immunotherapies, with the global CAR‑T market projected to exceed $15 billion by 2030. If G‑Link can deliver on its promise, it could accelerate the pipeline for solid‑tumor programs such as Vyriad’s VV169, reducing reliance on bespoke viral constructs and lowering manufacturing costs. Regulatory agencies have shown openness to platform‑based approaches, but will scrutinize safety of retargeted lentiviruses. Strategic partnerships with pharmaceutical firms could fast‑track clinical translation, making G‑Link a potential catalyst for broader adoption of in‑vivo cell therapies.